抗發炎治療藥物市場規模、佔有率和成長分析（按藥物類別、適應症、用途、通路和地區分類）－2026-2033年產業預測

預計到 2024 年，全球抗發炎治療市場規模將達到 1,073.2 億美元，到 2025 年將達到 1,124.7 億美元，到 2033 年將達到 1,636.5 億美元，預測期（2026-2033 年）的複合年成長率為 4.8%。

由於類風濕性關節炎、氣喘和發炎性腸道疾病（IBD）等自體免疫疾病和慢性發炎性疾病的盛行率不斷上升，全球抗發炎治療市場正經歷顯著成長。這些疾病給全球醫療保健系統帶來了持續的負擔。生物製藥和標靶治療顯著改善了治療效果，而生物相似藥則提高了成本效益，並改善了患者獲得先進療法的機會。生物相似藥驅動的市場競爭動態有助於減輕患者負擔，並拓寬治療選擇。此外，慢性發炎患者老年人口的成長預計將進一步推動市場需求。在研製生物製藥（尤其是針對白細胞介素路徑的生物製劑）的持續研發和潛在核准，可望支持市場的長期擴張，並促進抗發炎治療向精準醫療的轉變。

全球抗發炎治療市場促進因素

全球抗發炎治療市場受到自體免疫疾病（例如發炎性腸道疾病 (IBD)、乾癬、氣喘和類風濕性關節炎）日益普遍的顯著影響。光是關節炎就影響著數百萬人，推動了對先進治療方案的需求。不斷成長的患者群體凸顯了有效治療方案的緊迫性。因此，生物製藥及其生物相似藥在全球範圍內的接受度不斷提高，反映出人們正轉向採用更先進、更具標靶性的治療方法來有效治療這些致殘性疾病。因此，在不斷成長的患者需求的推動下，預計該市場將持續成長。

限制全球抗發炎治療市場發展的因素

全球抗發炎治療市場面臨嚴峻挑戰，生物製藥治療費用高昂，限制了患者的用藥途徑，尤其是在中低收入國家。諸如阿達木單抗（Humira）和其他生物製藥的年度治療費用可能非常高昂，令許多患者難以負擔。即使生物相似藥問世，治療費用仍是患者獲得治療的一大障礙。此外，保險覆蓋範圍的不均衡和報銷流程的延誤加劇了這些用藥難題，導致全球許多患者無法及時獲得適當的治療，最終阻礙了抗發炎療法在市場上的整體發展。

全球抗發炎治療藥物市場趨勢

全球抗發炎治療市場正日益呈現以標靶特定發炎路徑的工程化生物目標和先進小分子藥物為特徵的趨勢。 IL-23抑制劑、JAK抑制劑和FcRn標靶抗體等創新藥物正在推動治療策略從傳統免疫抑制劑轉向其他療法，並將治療範圍從罕見自體免疫疾病擴展到潰瘍性大腸炎等更常見的疾病。這一趨勢不僅提高了療效並最大限度地減少了副作用，而且隨著現有產品面臨來自學名藥和生物相似藥日益激烈的競爭，也帶來了巨大的商業性機會。因此，市場正朝著精準醫療的方向發展，有望實現更有效、更有針對性的發炎性疾病管理。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球抗發炎治療藥物市場規模（依藥物類別分類）及複合年成長率（2026-2033 年）

• 抗發炎生物製藥
• 非類固醇消炎劑（NSAIDs）
• 皮質類固醇

全球抗發炎治療藥物市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 關節炎
• 呼吸系統疾病
• 多發性硬化症
• 銀屑病
• 發炎性腸道疾病

全球抗發炎治療藥物市場規模（按應用領域分類）及複合年成長率（2026-2033 年）

• 自體免疫疾病
• 發炎性疾病
• 呼吸系統疾病

全球抗發炎治療藥物市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房

全球抗發炎治療藥物市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• AbbVie（USA）
• Johnson & Johnson（USA）
• Pfizer（USA）
• F. Hoffmann-La Roche（Switzerland）
• Novartis（Switzerland）
• Merck & Co., Inc.（USA）
• AstraZeneca（UK/Sweden）
• Bristol Myers Squibb（USA）
• Amgen（USA）
• Eli Lilly and Company（USA）
• Sanofi（France）
• GSK（GlaxoSmithKline）（UK）
• Bayer（Germany）
• Gilead Sciences（USA）
• Takeda Pharmaceutical Company（Japan）
• Teva Pharmaceutical Industries（Israel）
• Boehringer Ingelheim（Germany）
• Regeneron Pharmaceuticals（USA）
• Viatris（USA）
• UCB（Belgium）

結論與建議

Global Anti-Inflammatory Therapeutics Market size was valued at USD 107.32 Billion in 2024 and is poised to grow from USD 112.47 Billion in 2025 to USD 163.65 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026-2033).

The global anti-inflammatory therapeutics market is witnessing significant growth due to a rising prevalence of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, asthma, and inflammatory bowel disease (IBD), which consistently burden health systems worldwide. Biologics and targeted therapies have greatly improved treatment outcomes, while biosimilars introduce cost-effectiveness and greater accessibility to advanced treatments. Competitive market dynamics driven by biosimilars have led to reduced patient costs and increased options for therapies. Additionally, the aging population experiencing chronic inflammation is expected to further elevate demand. Ongoing development and anticipated approvals of pipeline biologics, particularly those targeting interleukin pathways, are set to bolster long-term market expansion and facilitate a shift toward precision medicine in anti-inflammatory treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Inflammatory Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Inflammatory Therapeutics Market Segments Analysis

Global Anti-Inflammatory Therapeutics Market is segmented by Drug Class, Indication, Application, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-Inflammatory Biologics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Corticosteroids. Based on Indication, the market is segmented into Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis and Inflammatory Bowel Disease. Based on Application, the market is segmented into Autoimmune, Inflammatory Diseases and Respiratory Diseases. Based on Distribution Channel, the market is segmented into Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is significantly influenced by the growing prevalence of autoimmune and chronic inflammatory conditions such as inflammatory bowel disease (IBD), psoriasis, asthma, and rheumatoid arthritis. With millions of individuals affected by arthritis alone, there is an escalating demand for advanced therapeutic solutions. This rise in patient populations underscores the urgent need for effective treatment options. As a result, biologics and their biosimilars are increasingly being embraced globally, reflecting a shift toward more sophisticated and targeted therapies to address these debilitating diseases effectively. The market is thus positioned for continued growth fueled by this rising patient demand.

Restraints in the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market faces significant challenges due to the high costs associated with biologic treatments, which limit patient access, particularly in low- to medium-income countries. The financial burden for therapies, such as Humira and other biologics, can reach astronomical figures annually, making them unaffordable for many. Even with the introduction of biosimilars, the issue of affordability persists, creating barriers to treatment. Furthermore, inconsistent insurance coverage and slow reimbursement processes exacerbate these accessibility problems, leaving numerous patients globally without timely or adequate care, ultimately hindering the overall progress of anti-inflammatory therapies in the market.

Market Trends of the Global Anti-Inflammatory Therapeutics Market

The Global Anti-Inflammatory Therapeutics market is increasingly characterized by the emergence of targeted biologics and sophisticated small molecules designed to address specific inflammatory pathways. Innovations such as IL-23 inhibitors, JAK inhibitors, and FcRn-targeting antibodies are directing a shift away from traditional immunosuppressants, expanding the applicability of treatments from rare autoimmune disorders to more common conditions like ulcerative colitis. This trend not only enhances therapeutic efficacy and minimizes side effects but also presents significant commercial opportunities as established products face mounting competition from generics and biosimilars. As a result, the market is evolving towards precision medicine, promising a more effective and targeted management of inflammatory diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anti-Inflammatory Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Anti-Inflammatory Biologics
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids

Global Anti-Inflammatory Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Arthritis
• Respiratory Diseases
• Multiple Sclerosis
• Psoriasis
• Inflammatory Bowel Disease

Global Anti-Inflammatory Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Autoimmune
• Inflammatory Diseases
• Respiratory Diseases

Global Anti-Inflammatory Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy

Global Anti-Inflammatory Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Indication, Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK (GlaxoSmithKline) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations